Genomic Health Patent Grants

Method to use gene expression to determine likelihood of clinical outcome of renal cancer

Granted: January 24, 2017
Patent Number: 9551034
The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.

Methods for depleting RNA from nucleic acid samples

Granted: April 14, 2015
Patent Number: 9005891
The invention relates to methods of depleting RNA from a nucleic acid sample. The RNA may be any RNA, including, but not limited to, rRNA, tRNA, and mRNA. The method is useful for depleting RNA from a nucleic acid sample obtained from a fixed paraffin-embedded tissue (FPET) sample. The method may also be used to prepare cDNA, in particular, a cDNA library for further analysis or manipulation.

Genes involved in estrogen metabolism

Granted: December 9, 2014
Patent Number: 8906625
The invention concerns genes that have been identified as being involved in estrogen metabolism, and are useful as diagnostic, prognostic and/or predictive markers in cancer. In particular, the invention concerns genes the tumor expression levels of which are useful in the diagnosis of cancers associated with estrogen metabolism, and/or in the prognosis of clinical outcome and/or prediction of drug response of such cancers.

Predicting response to chemotherapy using gene expression markers

Granted: October 21, 2014
Patent Number: 8868352
The present invention provides gene expression information useful for predicting whether a cancer patient is likely to have a beneficial response to treatment with chemotherapy, comprising measuring, in a biological sample comprising a breast tumor sample obtained from the patient, the expression levels of gene subsets to obtain a risk score associated with a likelihood of a beneficial response to chemotherapy, wherein the score comprises at least one of the following variables: (i)…

Genes involved in estrogen metabolism

Granted: August 19, 2014
Patent Number: 8808994
The invention concerns genes that have been identified as being involved in estrogen metabolism, and are useful as diagnostic, prognostic and/or predictive markers in cancer. In particular, the invention concerns genes the tumor expression levels of which are useful in the diagnosis of cancers associated with estrogen metabolism, and/or in the prognosis of clinical outcome and/or prediction of drug response of such cancers.

Methods of predicting cancer risk using gene expression in premalignant tissue

Granted: July 1, 2014
Patent Number: 8765383
The present disclosure provides methods for assessing a patient's cancer risk and/or recurrence risk, which methods comprise assaying, in a biological sample obtained from the gastrointestinal (GI) tract of the patient, an expression level of a risk gene. The present disclosure also provides methods involving a cancer risk/recurrence risk sequence, i.e. the V600E mutation of the BRAF gene, which is useful for assessing cancer risk and/or recurrence risk in a patient.

Gene expression markers for breast cancer prognosis

Granted: June 3, 2014
Patent Number: 8741605
The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of breast cancer.

Gene expression profile algorithm and test for determining prognosis of prostate cancer

Granted: May 13, 2014
Patent Number: 8725426
The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.

Gene expression markers for prediction of patient response to chemotherapy

Granted: January 21, 2014
Patent Number: 8632980
The present invention relates to gene sets useful in assessing prognosis and/or predicting the response of cancer, e.g. colorectal cancer to chemotherapy. In addition, the invention relates to a clinically validated cancer test, e.g. colorectal test, for assessment of prognosis and/or prediction of patient response to chemotherapy, using expression analysis. The present invention accommodates the use of archived paraffin embedded biopsy material for assay of all markers in the relevant…

Method and system to characterize transcriptionally active regions and quantify sequence abundance for large scale sequencing data

Granted: October 22, 2013
Patent Number: 8566039
This invention provides a quantitative method to determine transcriptionally active regions and quantify sequence abundance from large scale sequencing data. The invention also provides a system based on reference sequences to design and implement the method. The system processes large scale sequence data from high throughput sequencing, generates transcriptionally active region sequences as necessary, and quantifies the sequence abundance of the gene or transcriptionally active region.…

Gene expression markers for colorectal cancer prognosis

Granted: February 5, 2013
Patent Number: 8367345
A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.

Universal amplification of fragmented RNA

Granted: December 11, 2012
Patent Number: 8329398
The invention relates to methods of using fragmented RNA, such as RNA obtained from archived fixed paraffin-embedded tissue material (FPET RNA) or other clinically biopsied tissue specimens for universal gene expression profiling.

Predictors of patient response to treatment with EGF receptor inhibitors

Granted: September 25, 2012
Patent Number: 8273534
The present invention provides methods and compositions to facilitate determining whether an EGFR-expressing cancer in an individual is an EGFR inhibitor-responsive cancer, as well as methods for determining the likelihood that a patient having an EGFR-expressing cancer will exhibit a beneficial response to an EGFR inhibitor therapy. The methods generally involve determining a normalized expression level of a gene product that correlates with EGFR inhibitor responsiveness.

Gene expression markers for colorectal cancer prognosis

Granted: September 25, 2012
Patent Number: 8273537
A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.

Gene expression markers for breast cancer prognosis

Granted: June 26, 2012
Patent Number: 8206919
The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of breast cancer.

Gene expression markers for colorectal cancer prognosis

Granted: June 12, 2012
Patent Number: 8198024
A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.

Gene expression markers for colorectal cancer prognosis

Granted: April 10, 2012
Patent Number: 8153378
A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.

Gene expression markers for colorectal cancer prognosis

Granted: April 10, 2012
Patent Number: 8153379
A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.

Gene expression markers for colorectal cancer prognosis

Granted: April 10, 2012
Patent Number: 8153380
A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.

Gene expression profiling of EGFR positive cancer

Granted: April 3, 2012
Patent Number: 8148076
The present invention concerns prognostic markers associated with EGFR positive cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed tissue samples of EGFR-expressing cancer, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.